advertisement

---

1 General aspects (0)   1.1 Epidemiology (4)   1.2 Population genetics (1)   1.3 Pathogenesis (4)   1.4 Quality of life (2)   1.5 Glaucomas as cause of blindness (6)   1.6 Prevention and screening (4) 2 Anatomical structures in glaucoma (1)   2.1 Conjunctiva (0)   2.2 Cornea (6)   2.3 Sclera (0)   2.4 Anterior chamber angle (0)   2.5 Meshwork (2)     2.5.1 Trabecular meshwork (5)     2.5.2 Schlemms canal (0)     2.5.3 Scleral outlet channels (0)   2.6 Aqueous humor dynamics (0)     2.6.1 Production (0)     2.6.2 Outflow (0)       2.6.2.1 Trabecular meshwork (0)       2.6.2.2 Uveoscleral (0)     2.6.3 Compostion (0)   2.7 Episcleral veins and venous pressure (0)   2.8 Iris (0)   2.9 Ciliary body (2)   2.10 Lens (1)   2.11 Vitreous body (0)   2.12 Choroid, peripapillary choroid, peripapillary atrophy (0)   2.13 Retina and retinal nerve fibre layer (13)   2.14 Optic disc (6)   2.15 Optic nerve (2)   2.16 Chiasma and retrochiasmal central nervous system (0)   2.17 Stem cells (0)   2.20 Other (0) 3 Laboratory methods (1)   3.1 Microscopy (1)   3.2 Electron microscopy (0)   3.3 Immunohistochemistry (7)   3.4 Molecular genetics (0)     3.4.1 Linkage studies (10)     3.4.2 Gene studies (1)   3.5 Molecular biology incl. SiRNA (11)   3.6 Cellular biology (5)   3.7 Biochemistry (2)   3.8 Pharmacology (3)   3.9 Pathophysiology (2)   3.10 Immunobiology (0)   3.11 Pharmacogenetics (0)   3.12 Proteomics (0)   3.13 In vivo imaging (0)     3.13.1 Laser Scanning (0)       3.13.1.1 Confocal Scanning Laser Ophthalmoscopy (0)       3.13.1.2 Confocal Scanning Laser Polarimetry (0)     3.13.2 Optical Coherence Tomography (0)       3.13.2.1 Anterior Segment (0)       3.13.2.2 Posterior Segment (0)     3.13.3 RGC Imaging (0)     3.13.4 Other (0)   3.20 Other (2) 4 Tissue culture of ocular cells (0) 5 Experimental glaucoma; animal models (24)   5.1 Rodent (0)   5.2 Primates (0)   5.3 Other (0) 6 Clinical examination methods (0)   6.1 Intraocular pressure measurement; factors affecting IOP (18)     6.1.1 Devices, techniques (0)     6.1.2 Fluctuation, circadian rhythms (0)     6.1.3 Factors affecting IOP (0)   6.2 Tonography, aqueous flow measurement (see also 2.6) (1)   6.3 Biomicroscopy (slitlamp) (2)     6.3.1 Anterior segment (1)     6.3.2 Posterior segment (0)   6.4 Gonioscopy (1)   6.5 Ophthalmoscopy (0)   6.6 Visual field examination and other visual function tests (0)     6.6.1 Conventional manual (0)     6.6.2 Automated (4)     6.6.3 Special methods (e.g. color, contrast, SWAP etc.) (9)   6.7 Electro-ophthalmodiagnosis (5)   6.8 Photography (0)     6.8.1 Anterior segment (0)     6.8.2 Posterior segment (3)   6.9 Computerized image analysis (0)     6.9.1 Laser scanning (13)       6.9.1.1 Confocal Scanning Laser Ophthalmoscopy (0)       6.9.1.2 Confocal Scanning Laser Polarimetry (0)     6.9.2 Optical coherence tomography (9)       6.9.2.1 Anterior (0)       6.9.2.2 Posterior (0)     6.9.5 Other (1)   6.10 Fluorescein (ICG) angiography (0)     6.10.1 Anterior segment (0)     6.10.2 Posterior segment (0)   6.11 Bloodflow measurements (4)   6.12 Ultrasonography and ultrasound biomicroscopy (1)   6.13 Provocative tests (1)   6.19 Telemedicine (1)   6.20 Progression (6)   6.30 Other (2) 8 Refractive errors in relation to glaucoma (0)   8.1 Myopia (0)   8.2 Hypermetropia (0)   8.3 Contact lenses (0)   8.4 Refractive surgical procedures (2)   8.5 Other (0) 9 Clinical forms of glaucomas (0)   9.1 Developmental glaucomas (5)     9.1.1 Congenital glaucoma, Buphthalmos (1)     9.1.2 Juvenile glaucoma (0)     9.1.3 Syndromes of Axenfeld, Rieger, Peters, aniridia (0)     9.1.4 Other (0)   9.2 Primary open angle glaucomas (0)     9.2.1 Ocular hypertension (0)     9.2.2 Other risk factors for glaucoma (6)     9.2.3 Open angle glaucoma with elevated IOP (0)     9.2.4 Normal pressure glaucoma (4)   9.3 Primary angle closure glaucomas (6)     9.3.1 Acute primary angle closure glaucoma (pupillary block) (5)     9.3.2 Chronic primary angle closure glaucoma (pupillary block) (0)     9.3.3 Plateau iris syndrome (0)     9.3.4 Primary angle closure suspect (0)     9.3.5 Primary angle closure (0)     9.3.10 Other (2)   9.4 Glaucomas associated with other ocular and systemic disorders (0)     9.4.1 Steroid-induced glaucoma (2)     9.4.2 Glaucomas associated with disorders of the cornea, conjunctiva, sclera (0)       9.4.2.1 Iridocorneal endothelial syndrome (ICE, incl. irisatrophy) (1)       9.4.2.2 Posterior polymorphous dystrophy (0)       9.4.2.3 Fuchs' endothelial dystrophy (0)       9.4.2.5 Other (0)     9.4.3 Glaucomas associated with disorders of the iris and ciliary body (0)       9.4.3.1 Pigmentary glaucoma (0)       9.4.3.5 Other (0)     9.4.4 Glaucomas associated with disorders of the lens (0)       9.4.4.1 Exfoliation syndrome (6)       9.4.4.2 Glaucomas associated with cataracts (0)       9.4.4.3 Glaucomas associated with lens dislocation (0)       9.4.4.5 Other (0)     9.4.5 Glaucomas associated with disorders of the retina, choroid and vitreous (1)       9.4.5.1 Neovascular glaucoma (2)       9.4.5.5 Other (0)     9.4.6 Glaucomas associated with inflammation, uveitis (4)     9.4.7 Glaucomas associated with ocular trauma (0)     9.4.8 Glaucomas associated with intraocular tumors (0)     9.4.9 Glaucomas associated with elevated episcleral venous pressure (0)       9.4.10 Glaucomas associated with hemorrhage (0)     9.4.11 Glaucomas following intraocular surgery (0)       9.4.11.1 Ciliary block (malignant) glaucoma (0)       9.4.11.2 Glaucomas in aphakia and pseudophakia (0)       9.4.11.3 Epithelial, fibrous, and endothelial proliferation (0)       9.4.11.4 Glaucomas associated with corneal surgery (0)       9.4.11.5 Glaucomas associated with vitreoretinal surgery (0)     9.4.15 Glaucoma in relation to systemic disease (3)     9.4.20 Other (0) 10 Differential diagnosis e.g. anterior and posterior ischemic optic neuropathy (2) 11 Medical treatment (0)   11.1 General management, indication (4)   11.2 Cholinergic drugs (0)   11.3 Adrenergic drugs (1)     11.3.1 Epinephrine (0)     11.3.2 Thymoxamine, dapiprazole (0)     11.3.3 Apraclonidine, brimonidine (2)     11.3.4 Betablocker (10)     11.3.5 Other (0)   11.4 Prostaglandins (15)   11.5 Carbonic anhydrase inhibitors (2)     11.5.1 Systemic (0)     11.5.2 Topical (2)   11.6 Osmotic treatment (0)   11.7 Treatment of bloodflow (1)   11.8 Neuroprotection (8)   11.9 Gene therapy (0)   11.13 Combination therapy (0)     11.13.1 Betablocker and pilocarpine (0)     11.13.2 Betablocker and carbon anhydrase inhibitor (0)     11.13.3 Betablocker and brimonidine (0)     11.13.4 Betablocker and prostaglandin (0)     11.13.5 Other (0)   11.14 Investigational drugs; pharmacological experiments (8)   11.15 Other drugs in relation to glaucoma (2)   11.16 Vehicles, delivery systems, pharmacokinetics, formulation (5)   11.17 Cooperation with medical therapy e.g. persistency, compliance, adherence (6)   11.20 Other (0) 12 Surgical treatment (0)   12.1 General management, indication (1)   12.2 Laser iridotomy (1)   12.3 Laser iridoplasty (0)   12.4 Laser trabeculoplasty and other laser treatment of the angle (3)   12.7 Surgical iridectomy (1)   12.8 Filtering surgery (0)     12.8.1 Without tube implant (10)     12.8.2 With tube implant or other drainage devices (9)     12.8.3 Non-perforating (3)     12.8.4 Using laser (0)     12.8.5 Other (0)     12.8.10 Woundhealing antifibrosis (8)     12.8.11 Complications, endophthalmitis (3)   12.9 Trabeculotomy, goniotomy (1)   12.10 Cyclodestruction (2)   12.11 Cyclodialysis (0)   12.12 Cataract extraction (1)     12.12.1 Intracapsular (0)     12.12.2 Extracapsular (0)     12.12.3 Phacoemulsification (9)   12.14 Combined cataract extraction and glaucoma surgery (0)     12.14.1 Intracapsular (0)     12.14.2 Extracapsular (0)     12.14.3 Phacoemulsification (2)   12.15 Capsulotomy (0)   12.16 Vitrectomy (0)   12.17 Anesthesia (1)   12.20 Other (1) 13 Therapeutic prognosis and outcome (0)   13.1 Prognostic factors (0)   13.2 Outcome (0)     13.2.1 IOP (0)     13.2.2 Visual field (0)       13.2.2.1 Progression (0)       13.2.2.2 Improvement (0)     13.2.3 Other (0) 14 Costing studies; pharmacoeconomics (7) 15 Miscellaneous (7)

---

Abstract #13519 Published in IGR 8-1

Vasoactive responses of U46619, PGF_2α, latanoprost, and travoprost in isolated porcine ciliary arteries

Vysniauskiene I; Allemann R; Flammer J; Haefliger IO
Investigative Ophthalmology and Visual Science 2006; 47: 295-298

---

PURPOSE: To compare the vasoactive properties of the prostanoids U46619 (thromboxane A2 analogue), prostaglandin F_2α (PGF_2α ), latanoprost free acid, and travoprost free acid in isolated porcine ciliary arteries. METHODS: In a myograph system (isometric force measurement), quiescent vessels were exposed (cumulatively) to U46619, PGF_2α , latanoprost, or travoprost (0.1 nM-0.1 mM). Experiments were also conducted in the presence of SQ 29548 (TP-receptor antagonist; 3-10 μM) or AL-8810 (FP-receptor antagonist; 3-30 μM). Contractions were expressed as the percentage of 100 mM potassium chloride-induced contractions. RESULTS: In quiescent vessels, contractions (concentration-response curves) induced by (0.1 mM) PGF_2α (87.9% ± 3.5%), U46619 (66.7% ± 4.1%), and latanoprost (62.9% ± 3.6%) were more pronounced (P ≤ 0.001) than those induced by travoprost (23.0% ± 4.4%). Concentration-response curves for PGF_2α , latanoprost, and travoprost were preceded by a smaller contraction peak (0.1 μM) that was higher (P ≤ 0.05) for travoprost (24.4% ± 2.8%) than for PGF_2α (12.9% ± 4.6%), but not different (P = 0.58) from latanoprost (22.0% ± 3.0%). The 50% maximal contraction (PD50: negative log M concentration) of U46619 (-8.05± 0.13) was lower (P ≤ 0.001) than those of latanoprost (-5.65 ± 0.10), PGF_2α (-5.49 ± 0.14), and travoprost (-5.12 ± 0.52). Contractions were inhibited (P ≤ 0.05-0.001) either by SQ 29548 or AL-8810. CONCLUSIONS: In isolated porcine ciliary arteries, all prostanoids tested induced contractions. Among them, travoprost appeared to be the least potent and U46619 the most efficient.

Dr. I. Vysniauskiene, Laboratory of Pharmacology and Physiology, University Eye Clinic, Basel, Switzerland

---

Classification:

3.20 Other (Part of: 3 Laboratory methods)
11.4 Prostaglandins (Part of: 11 Medical treatment)

---

• ← Previous
• Next →

---